UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
A UC San Diego pilot study on parents of mass shooting victims finds that eight weeks of mindfulness training is effective in reducing trauma, depression, stress and grief caused by gun violence.
UC San Diego study finds new screening tool flags 95 percent of stage 1 pancreatic cancers.
UC San Diego Health is now administering Evusheld to eligible, immunocompromised patients to protect against the COVID-19 virus.
Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. Researchers at UC San Diego’s Scripps Institution of Oceanography found that an enzyme called SalC assembles what the team calls the salinosporamide anti-cancer “warhead.”
UC San Diego study shows neuroendocrine cells in the lungs drive a developmental lung disease, and a similar brain-lung interaction may contribute to COVID-19 symptoms. The findings suggest neuropeptides may be a promising therapeutic target for conditions with excess lung fluid.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
